Engitix Collaborates With Dompé On Fibrosis And Cancer As It Eyes The Clinic
The UK biotech has struck up an unusual deal with its new investor that lets it retain control over its assets, as it raises $54m in a series A.
The UK biotech has struck up an unusual deal with its new investor that lets it retain control over its assets, as it raises $54m in a series A.